Dr. Andrew Hill
Andrew is an expert in drug development and costing. He is currently a Senior Visiting Research Fellow in Liverpool University’s Pharmacology Department.
Dr Andrew Hill has over 20 years of experience working in drug development and costing. He is a Senior Visiting Research Fellow in Liverpool University’s Pharmacology Department focussing on treatment access issues, particularly for HIV, viral hepatitis, TB and cancer.
Andrew has been an advisor to the World Health Organization (WHO) and the Clinton Health Access Initiative (CHAI) since 2015 providing guidance on HIV treatments and designing clinical trial programmes for antiretroviral dose optimisation. Andrew is also a Member of the WHO Fair Pricing Committee, which discusses challenges in – and solutions for – current medicine pricing systems. Previously, Andrew worked on the development of HIV antiretrovirals, and advised pharmaceutical firms on the design and analysis of clinical trials and drug development.
Andrew is the author of over 40 research papers on HIV and has been involved in the use of HIV RNA and CD4 counts in the regulatory approval of antiretrovirals, the standardisation of HIV clinical trial analyses, and several systematic reviews of HIV clinical trials. He has been on the editorial board of “AIDS” and runs a charity, “Living and Loving” which supports children with HIV and AIDS in Thailand.